Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2019

View Archived Issues

CD7 could target CAR T cells to AML

Long life in the SLO lane

Cross-species analysis identifies NSD2 as a key regulator of metastatic prostate cancer progression

Design and synthesis of novel imidazole-biaryl-tetrazole-based GSNOR inhibitors for COPD

Preclinical data presented for sarecycline for the treatment of acne vulgaris

Roche presents cannabinoid CB2 receptor inverse agonists

Phase III JEWEL study of lurasidone meets primary endpoint in patients with schizophrenia

Pfizer identifies muscarinic M4 receptor PAMs

Takeda Pharmaceutical divulges muscarinic M1 receptor PAMs

Common mechanism links diverse anemias

Protagonist Therapeutics initiates phase II study of PTG-300 in patients with beta-thalassemia

Bristol-Myers Squibb presents phase II data for pegbelfermin in non-alcoholic steatohepatitis

Patient enrollment ongoing in first in human trial of CPI-100

Novel piperazinyl pyrrolidin-2-ones reversibly inhibiting MGL

Blade Therapeutics patents calpain inhibitors

Regulator of calcineurin 1 suppresses nonshivering thermogenesis by two different mechanisms

First subject dosed in phase I study of the anti-AXL antibody BGB-149

Mitokinin discloses new PINK1 modulators

Pluristem reports successful case study in treatment of Buerger's disease patient

miRagen Therapeutics reports new phase I data on cobomarsen in CTCL, ATLL and DLBCL

OncoImmune completes phase II study of CD24Fc for acute GvHD prophylaxis

Beijing InnoCare begins first-in-human study of ICP-192 in advanced solid tumors

Theravance opens phase III study of TD-9855 to treat symptomatic neurogenic orthostatic hypotension

Regeneron initiates phase I/II study of REGN-5458 in relapsed or refractory multiple myeloma

First-in-human trial investigates RIPK1 inhibitor GSK-3145095 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...